Non-Hodgkin’s lymphoma unspecified histology aggressive recurrent – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Sun, 31 May 2026 04:01:50 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Non-Hodgkin’s lymphoma unspecified histology aggressive recurrent – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Effectiveness and Safety of Odronextamab Compared to Standard Treatment in Adults with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-odronextamab-compared-to-standard-treatment-in-adults-with-relapsed-or-refractory-aggressive-b-cell-non-hodgkin-lymphoma/ Wed, 29 Apr 2026 14:26:59 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-odronextamab-compared-to-standard-treatment-in-adults-with-relapsed-or-refractory-aggressive-b-cell-non-hodgkin-lymphoma/ This clinical trial is focused on studying a type of cancer called B-cell non-Hodgkin’s lymphoma, which is a cancer that affects the lymphatic system, part of the body’s immune system. The study is evaluating a new treatment called odronextamab (also known by its code name REGN1979), which is a special type of medication known as a bispecific antibody. This means it is designed to target two different proteins at once, potentially helping the immune system to better fight the cancer. The trial aims to compare the effectiveness and safety of odronextamab against the standard treatments currently used for this type of cancer.

Participants in the study will receive either odronextamab or one of the standard treatments, which may include medications like cisplatin, gemcitabine, carboplatin, dexamethasone, cytarabine, rituximab, etoposide, or ifosfamide. These treatments are given through an intravenous infusion, which means they are delivered directly into the bloodstream through a vein. The study will last for several months, during which participants will be closely monitored by healthcare professionals to assess how well the treatments are working and to check for any side effects.

The main goal of the study is to see how long participants can live without their cancer getting worse, which is known as event-free survival. Other aspects being studied include how long participants live overall, how their quality of life changes, and how their bodies respond to the treatments. This information will help researchers understand if odronextamab could be a better option for treating aggressive B-cell non-Hodgkin’s lymphoma compared to the current standard treatments.

]]>